keyword
MENU ▼
Read by QxMD icon Read
search

Her2 positive, hormone positive

keyword
https://www.readbyqxmd.com/read/29336185/an-update-on-first-line-therapies-for-metastatic-breast-cancer
#1
Palma Fedele, Mariangela Ciccarese, Giammarco Surico, Saverio Cinieri
In recent years, outcomes of patients with metastatic breast cancer (MBC) have improved due to a greater understanding of the mechanisms of carcinogenesis in the development of newer molecularly targeted drugs, especially those as a front-line therapy. Remarkable improvements have been made in the treatment of hormone receptor positive (HR+) and Her2 positive MBC and currently targeted treatment strategies represent a valid first line treatment. Areas covered: Herein, the authors provide an overview of the first-line pharmacotherapies currently available for the treatment of MBC and provide their expert perspectives on the area...
January 16, 2018: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29332137/variation-in-guideline-concordant-care-for-elderly-patients-with-metastatic-breast-cancer-in-the-united-states
#2
Philip D Poorvu, Ines Vaz-Luis, Rachel A Freedman, Nancy U Lin, William T Barry, Eric P Winer, Michael J Hassett
PURPOSE: Prior studies have identified shortcomings in the quality of care for early-stage breast cancer. Guidelines recommend systemic therapy for metastatic breast cancer (MBC), but few studies have examined guideline concordance for these patients. METHODS: We used Surveillance, Epidemiology, and End Results (SEER)-Medicare data to identify patients aged ≥ 66 diagnosed in 2010-2011 with de novo MBC who were continuously enrolled in fee-for-service Medicare...
January 13, 2018: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29330212/early-and-locally-advanced-metaplastic-breast-cancer-presentation-and-survival-by-receptor-status-in-surveillance-epidemiology-and-end-results-seer-2010-2014
#3
Mary C Schroeder, Priya Rastogi, Charles E Geyer, Lance D Miller, Alexandra Thomas
BACKGROUND: Metaplastic breast cancer (MBC) is a rare disease subtype characterized by an aggressive clinical course. MBC is commonly triple negative (TN), although hormone receptor (HR) positive and human epidermal growth receptor 2 (HER2) positive cases do occur. Previous studies have reported similar outcomes for MBC with regard to HR status. Less is known about outcomes for HER2 positive MBC. MATERIALS AND METHODS: Surveillance, Epidemiology, and End Results Program data were used to identify women diagnosed 2010-2014 with MBC or invasive ductal carcinoma (IDC)...
January 12, 2018: Oncologist
https://www.readbyqxmd.com/read/29326029/neoadjuvant-treatment-with-trastuzumab-and-pertuzumab-plus-palbociclib-and-fulvestrant-in-her2-positive-er-positive-breast-cancer-na-pher2-an-exploratory-open-label-phase-2-study
#4
Luca Gianni, Giancarlo Bisagni, Marco Colleoni, Lucia Del Mastro, Claudio Zamagni, Mauro Mansutti, Milvia Zambetti, Antonio Frassoldati, Raffaella De Fato, Pinuccia Valagussa, Giuseppe Viale
BACKGROUND: In the neoadjuvant setting, blockade of HER2 plus use of an aromatase inhibitor in patients with HER2-positive and oestrogen receptor (ER)-positive breast cancer leads to a pathological complete response in 21% of patients. Convergence of HER2 and ER signals on RB1 suggests that a combined pharmacological intervention directed to these targets could be synergistic. To test this approach, we combined palbociclib to block RB1, fulvestrant to block ER, and trastuzumab with pertuzumab to block HER2 in patients with HER2-positive, ER-positive breast cancer...
January 8, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29323058/assessment-of-topoisomerase-ii-alpha-gene-status-by-dual-color-chromogenic-in-situ-hybridization-in-a-set-of-iraqi-patients-with-invasive-breast-carcinoma
#5
Rasha Abd Alraouf Neama, Manal A Habib, Sahira A Ali, Ali H Al-Khafaji, Mohammed F Alqanbar
BACKGROUND: The human epidermal growth factor receptor 2(HER2) proto-oncogene is overexpressed or amplified in approximately 15%-25% of invasive breast cancers. Approximately 35% of HER2-amplified breast cancers have coamplification of the topoisomerase II-alpha (TOP2A) gene encoding an enzyme that is a major target of anthracyclines. Hence, the determination of genetic alteration (amplification or deletion) of both genes is considered as an important predictive factor that determines the response of breast cancer patients to treatment...
October 2017: Indian Journal of Pathology & Microbiology
https://www.readbyqxmd.com/read/29315431/receptor-conversion-in-distant-breast-cancer-metastases-a-systematic-review-and-meta-analysis
#6
Willemijne A M E Schrijver, Karijn P M Suijkerbuijk, Carla H van Gils, Elsken van der Wall, Cathy B Moelans, Paul J van Diest
Background: In metastatic breast cancer, hormone and/or human epidermal growth factor receptor 2 (HER2)-targeted therapy decision-making is still largely based on tissue characteristics of the primary tumor. However, a change of estrogen receptor alpha (ERα), progesterone receptor (PR), and HER2 status in distant metastases has frequently been reported. The actual incidence of this phenomenon has been debated. Methods: We performed a meta-analysis including 39 studies assessing receptor conversion from primary breast tumors to paired distant breast cancer metastases...
January 5, 2018: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/29313063/using-gene-expression-data-to-direct-breast-cancer-therapy-evidence-from-a-preclinical-trial
#7
REVIEW
Shams Reaz, Deimante Tamkus, Eran R Andrechek
The heterogeneity both within and between breast cancers presents a significant clinical challenge for both diagnosis and therapy. This heterogeneity is present at all levels of analysis in breast cancer, ranging from genomic to metabolomic. A function of this heterogeneity is that numerous signaling networks are activated, and while treatment of one arm may be initially effective, this allows the tumor to be poised to evolve a resistance mechanism. Here we review the classification of breast cancers and discuss therapy of hormone positive, HER2 positive, and triple negative breast cancers...
January 8, 2018: Journal of Molecular Medicine: Official Organ of the "Gesellschaft Deutscher Naturforscher und Ärzte"
https://www.readbyqxmd.com/read/29310037/a-nationwide-registry-based-cohort-study-of-the-mammaprint-genomic-risk-classifier-in-invasive-breast-cancer
#8
Floris H Groenendijk, Agnes Jager, Fatima Cardoso, Carolien H M van Deurzen
AIM: To evaluate the use of the MammaPrint assay, a 70-gene risk signature for early breast cancers, and to correlate genomic risk stratification with individual clinicopathological parameters and clinical risk as assessed by Adjuvant! Online. METHODS: A Dutch Pathology Registry (PALGA)-based cohort study consisting of 1916 patients for which 1946 MammaPrint assay results were synoptically reported from 2013 to 2016. We could retrospectively assess clinical risk for 1146 tumors (58...
January 5, 2018: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29306660/clinical-impact-of-21-gene-recurrence-score-test-within-the-veterans-health-administration-utilization-and-receipt-of-guideline-concordant-care
#9
Leland E Hull, Julie A Lynch, Brygida B Berse, Scott L DuVall, Danielle S Chun, Vicki L Venne, Olga V Efimova, Michael S Icardi, Michael J Kelley
INTRODUCTION: Ensuring guideline-concordant cancer care is a Department of Veterans Affairs (VA) priority, especially as the number of breast cancer patients at VA medical centers (VAMCs) grows. We assessed the utilization and clinical impact of the 21-gene Recurrence Score test, which predicts 10-year risk of breast cancer recurrence and the likelihood of chemotherapy benefit, on veterans newly diagnosed with breast cancer. PATIENTS AND METHODS: We conducted a retrospective cohort study using 2011-2012 VA Central Cancer Registry, chart review, and laboratory test data...
November 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29306221/breast-cancer-survival-in-soweto-johannesburg-south-africa-a-receptor-defined-cohort-of-women-diagnosed-from-2009-to-11
#10
Herbert Cubasch, Caroline Dickens, Maureen Joffe, Raquel Duarte, Nivashni Murugan, Ming Tsai Chih, Kiashanee Moodley, Vinay Sharma, Oluwatosin Ayeni, Judith S Jacobson, Alfred I Neugut, Valerie McCormack, Paul Ruff
BACKGROUND: South Africa's public healthcare system is better equipped to manage breast cancer than most other SSA countries, but survival rates are unknown. METHODS: A historical cohort of 602 women newly diagnosed with invasive breast carcinoma during 2009-2011 at Chris Hani Baragwanath Academic Hospital, Soweto, Johannesburg, was followed using health systems data to December 2014. 'Overall survival' time was defined from diagnosis to death or terminal illness...
January 3, 2018: Cancer Epidemiology
https://www.readbyqxmd.com/read/29305309/evaluation-of-prognosis-in-hormone-receptor-positive-her2-negative-and-lymph-node-negative-breast-cancer-with-low-oncotype-dx-recurrence-score
#11
Jane Meisel, Chao Zhang, Cameron Neely, Pia Mendoza, Shuo You, Tatiana Han, Yuan Liu, Aysegul A Sahin, Ruth O'Regan, Xiaoxian Li
INTRODUCTION: Hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancers without lymph node metastasis have good prognosis. We compared the prognosis of hormone receptor-positive, HER2-negative, lymph node-negative cancers with Oncotype DX score ranges of 1 to 10 (1-10 group) and 11 to < 18 (11-18 group). PATIENTS AND METHODS: A total of 107 cases in the 1-10 group and 225 cases in the 11-18 group were reviewed. All patients received surgery...
December 14, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/29302853/progesterone-receptor-pgr-gene-variants-associated-with-breast-cancer-and-associated-features-a-case-control-study
#12
Rabeb M Ghali, Maryam A Al-Mutawa, Bashayer H Ebrahim, Hanen H Jrah, Sonia Zaied, Hanen Bhiri, Fahmi Hmila, Touhami Mahjoub, Wassim Y Almawi
Insofar as altered estrogen receptor-progesterone receptor (PR) expression contribute to breast cancer pathogenesis, previous studies examined the association of genetic variation in PR gene (PGR) with breast cancer, but with mixed outcome. We evaluated the association between PGR variants, and breast cancer and associated features. A retrospective case-control study involving 183 female breast cancer patients, and 222 control women. PGR genotyping was done by real-time PCR. Minor allele frequencies of rs1042838, rs590688, and rs10895068 PGR gene polymorphisms were significantly higher in breast cancer patients compared to controls...
January 4, 2018: Pathology Oncology Research: POR
https://www.readbyqxmd.com/read/29291541/her-2-positive-mucinous-carcinoma-breast-cancer-case-report
#13
Irean Garcia Hernandez, Mauricio Canavati Marcos, Margarita Garza Montemayor, Dulce Lopez Sotomayor, Diana Pineda Ochoa, Gabriela Sofia Gomez Macias
INTRODUCTION: Mucinous carcinoma is a variant of invasive breast carcinomas that accounts for 2% of them and has a better prognosis in contrast to the non-specific invasive carcinoma. They regularly are positive for estrogen and progesterone receptors and, generally, they do not overexpress HER2. When HER2 is positive, the first line treatment is trastuzumab; although the resistance is 52-89% for the non-specific carcinoma, it has been described just once in mucinous carcinoma. CASE SUMMARY: A 48-year-old female presented with a lump in her right breast and after a biopsy, it was diagnosed as mucinous carcinoma in the core biopsy and surgical resection, with positive hormone receptors and HER2 positive (3+) in 100% of the tumor cells...
December 26, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29287189/human-epidermal-growth-factor-receptor-2-dual-blockade-with-trastuzumab-and-pertuzumab-in-real-life-italian-clinical-practice-versus-the-cleopatra-trial-results
#14
Sabino De Placido, Mario Giuliano, Francesco Schettini, Claudia Von Arx, Giuseppe Buono, Ferdinando Riccardi, Daniela Cianniello, Roberta Caputo, Fabio Puglisi, Marta Bonotto, Alessandra Fabi, Domenico Bilancia, Mariangela Ciccarese, Vito Lorusso, Andrea Michelotti, Dario Bruzzese, Bianca Maria Veneziani, Mariavittoria Locci, Michelino De Laurentiis, Grazia Arpino
OBJECTIVES: Given their inclusion and exclusion criteria, randomized clinical trials (RCT) might not include a population that truly mirrors real life (RL). This raises concerns about the applicability of RCT results in clinical practice. We evaluated the efficacy of anti-HER2 treatment with pertuzumab combined with trastuzumab and a taxane as first-line treatment for HER2-positive metastatic breast cancer in a RL setting, and compared the safety results obtained in our population versus the experimental cohort of the CLEOPATRA RCT, which led to the approval of this therapy...
December 26, 2017: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/29286222/brca1-promoter-methylation-and-expression-associations-with-er-pr-and-her2-subtypes-of-breast-carcinoma
#15
Mohit Kumar, Ram Krishna Sahu, Aditi Goyal, Sonal Sharma, Navneet Kaur, Ravi Mehrotra, Usha Rani Singh, Suresh Hedau
Introduction: Considering the increasing trend in incidence rates, morbidity and mortality of breast cancer, there is an urgent need to identify and validate new biomarkers for early detection and better management. The purpose of the study was to investigate BRCA1 protein expression and promoter methylation of the BRCA1 gene and their association with molecular subtypes based on estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) positivity. Materials and Methods: A total of 114 breast cancer tissue biopsies were collected for methylation specific PCR (MSP) and immunohistochemical (IHC) analysis...
December 29, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/29282695/strategies-and-progress-of-endocrine-therapy-for-patients-with-metastatic-breast-cancer
#16
Hope S Rugo, Huiping Li, Xinyu Gui
Breast cancer is one of the most prevalent cancers and the leading causes of cancer mortality in women worldwide and in China. For hormone receptor-positive (HR+) breast cancer, accounting for approximately 60-80% of breast cancer, endocrine therapy (ET) is the primary treatment strategy. For patients with HR+ metastatic breast cancer (MBC), there are many endocrine-based treatment options that can improve long-term outcomes and optimize quality of life. With the emergence and availability of new and effective agents, the options for ET have expanded in the last two decades...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29282021/prediction-of-survival-after-neoadjuvant-chemotherapy-for-breast-cancer-by-evaluation-of-tumor-infiltrating-lymphocytes-and-residual-cancer-burden
#17
Yuka Asano, Shinichiro Kashiwagi, Wataru Goto, Koji Takada, Katsuyuki Takahashi, Takaharu Hatano, Satoru Noda, Tsutomu Takashima, Naoyoshi Onoda, Shuhei Tomita, Hisashi Motomura, Masahiko Ohsawa, Kosei Hirakawa, Masaichi Ohira
BACKGROUND: The tumor immune environment not only modulates the effects of immunotherapy, but also the effects of other anticancer drugs and treatment outcomes. These immune responses can be evaluated with tumor-infiltrating lymphocytes (TILs), which has frequently been verified clinically. On the other hand, residual cancer burden (RCB) evaluation has been shown to be a useful predictor of survival after neoadjuvant chemotherapy (NAC). In this study, RCB and TILs evaluations were combined to produce an indicator that we have termed "RCB-TILs", and its clinical application to NAC for breast cancer was verified by subtype-stratified analysis...
December 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29275435/homologous-recombination-deficiency-hrd-status-predicts-response-to-standard-neoadjuvant-chemotherapy-in-patients-with-triple-negative-or-brca1-2-mutation-associated-breast-cancer
#18
Melinda L Telli, Jessica Hellyer, William Audeh, Kristin C Jensen, Shikha Bose, Kirsten M Timms, Alexander Gutin, Victor Abkevich, Rebecca N Peterson, Chris Neff, Elisha Hughes, Zaina Sangale, Joshua Jones, Anne-Renee Hartman, Pei-Jen Chang, Shaveta Vinayak, Richard Wenstrup, James M Ford
PURPOSE: Defects in the homologous recombination (HR) DNA repair pathway sensitize tumors to therapeutics that target this pathway. A significant proportion of triple-negative breast cancers (TNBC) carry HR defects. The HRD assay is highly associated with sensitivity to neoadjuvant platinum-based chemotherapy in TNBC. Standard chemotherapy consists of some combination of an anthracycline, cyclophosphamide, and taxane. This study assesses the association of HR deficiency status with response to standard neoadjuvant chemotherapy in TNBC or BRCA1/2 mutation-associated breast cancer...
December 23, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/29273958/biomarkers-in-breast-cancer-a-consensus-statement-by-the-spanish-society-of-medical-oncology-and-the-spanish-society-of-pathology
#19
R Colomer, I Aranda-López, J Albanell, T García-Caballero, E Ciruelos, M Á López-García, J Cortés, F Rojo, M Martín, J Palacios-Calvo
This consensus statement revises and updates the recommendations for biomarkers use in the diagnosis and treatment of breast cancer, and is a joint initiative of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. This expert group recommends determining in all cases of breast cancer the histologic grade and the alpha-estrogen receptor (ER), progesterone receptor, Ki-67 and HER2 status, in order to assist prognosis and establish therapeutic options, including hormone therapy, chemotherapy and anti-HER2 therapy...
December 22, 2017: Clinical & Translational Oncology
https://www.readbyqxmd.com/read/29261249/real-world-economic-value-of-a-21-gene-assay-in-early-stage-breast-cancer
#20
Stanley E Waintraub, Donna McNamara, Deena Mary Atieh Graham, Andrew L Pecora, John Min, Tommy Wu, Hyun Gi Noh, Jacqueline Connors, Ruth Pe Benito, Kelly Choi, Eric Schultz, Stuart L Goldberg
OBJECTIVES: Value-based payment reforms shift cost-containment responsibilities to the physician. Although gene expression profiling (GEP) utilizing a 21-gene panel among patients with early-stage, axillary lymph node-negative, hormone receptor-positive, HER2/neu oncogene-negative breast cancer is able to identify a cohort that may achieve excellent outcomes without adjuvant chemotherapy, high up-front costs (list price, $4175) could dissuade usage. STUDY DESIGN: Retrospective review of consecutive patients with breast cancer treated at a single cancer center...
December 1, 2017: American Journal of Managed Care
keyword
keyword
21972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"